University of Cambridge spin-out BlueGnome, which specialises in the screening of genetic abnormalities associated with developmental delay, cancer and infertility, has been sold to US-based life sciences company Illumina. The firm is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function.
A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.
A new technology which delivers sustained release of therapeutics for up to six months could be used in conditions which require routine injections, including diabetes, certain forms of cancer and potentially HIV/AIDS.
For generations, we have dreamed of machines with artificial intelligence with which we can have real conversations but, despite amazing technological advances, such devices seem some way off. Now researchers at Cambridge are changing the picture, by remodelling the essence of spoken dialogue systems.
The University of Cambridge and National Research Foundation, Singapore, have today announced plans for a collaborative research centre, specialising in energy efficient, low-carbon chemical process technology.
Income generated from the University of Cambridge’s commercialisation activities continued to rise in 2011, as did the number of intellectual property, consultancy and equity agreements signed on behalf of the University and its researchers.